{"filing":{"accession_number":"0001193125-26-396094","cik":"0001645460","ticker":"CUE","company_name":"Cue Biopharma, Inc.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-20","primary_document":"d21238d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526396094/d21238d8k.htm"},"events":[{"id":33881,"run_id":31184,"accession_number":"0001193125-26-396094","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Cue Biopharma announced positive Phase 2 clinical trial results for CUE-221 in chronic spontaneous urticaria, with the primary endpoint met at all dose levels and a key secondary endpoint met at the highest dose, demonstrating a favorable safety profile. The company plans to advance to Phase 2b/3 registration-enabling study in CSU and Phase 2 in food allergy.","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37456,"accession_number":"0001193125-26-396094","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces positive Phase 2 clinical trial results for CUE-221 in chronic spontaneous urticaria, including achievement of primary and key secondary endpoints with statistical significance and a favorable safety profile. While this is a material clinical milestone for a biopharmaceutical company that would affect investor assessment of the drug candidate's viability and the company's prospects, it does not fit the \"earnings_release\" category (which typically applies to financial results disclosures) nor any other specific event type. The event is clearly operational/strategic in nature—a significant clinical development milestone—making \"operational_other\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T12:05:00.593256+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37457,"accession_number":"0001193125-26-396094","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in chronic spontaneous urticaria (CSU), with the primary endpoint met at all dose levels and key secondary endpoint met at the highest dose. The company plans to advance to Phase 2b/3 registration-enabling study in CSU and Phase 2 in food allergy. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other named event types—it is a significant operational/strategic advancement in drug development that would affect investor assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T12:05:00.593256+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37456,"accession_number":"0001193125-26-396094","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces positive Phase 2 clinical trial results for CUE-221 in chronic spontaneous urticaria, including achievement of primary and key secondary endpoints with statistical significance and a favorable safety profile. While this is a material clinical milestone for a biopharmaceutical company that would affect investor assessment of the drug candidate's viability and the company's prospects, it does not fit the \"earnings_release\" category (which typically applies to financial results disclosures) nor any other specific event type. The event is clearly operational/strategic in nature—a significant clinical development milestone—making \"operational_other\" the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T12:05:00.593256+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-09-21"},{"id":37457,"accession_number":"0001193125-26-396094","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in chronic spontaneous urticaria (CSU), with the primary endpoint met at all dose levels and key secondary endpoint met at the highest dose. The company plans to advance to Phase 2b/3 registration-enabling study in CSU and Phase 2 in food allergy. This is a material clinical development milestone for a clinical-stage biopharmaceutical company, but does not fit the specific categories of earnings release, M\u0026A, restatement, or other named event types—it is a significant operational/strategic advancement in drug development that would affect investor assessment of the company's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T12:05:00.593256+00:00","company_name":"Cue Biopharma, Inc.","ticker":"CUE","filing_date":"2026-09-21"}]}